North America
Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
Princeton, NJ and TOKYO, May 8, 2024 - Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.
Age-related macular degeneration (AMD) is a leading cause of severe vision loss for people aged 50 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals. With the increase in life expectancy, the number of reported cases of AMD will increase, continuing to add to the substantial burden already on patients, caretakers, and on health care system.
Neovascular (wet) AMD (nAMD) is characterized by abrupt central vision loss caused by abnormal blood vessel growth and leakage in the macular a
08 May 2024